Why the study?
Does oral apixaban improve the treatment of cancer-associated venous thromboembolism without increasing major bleeding compared to subcutaneous dalteparin?
Does oral apixaban improve the treatment of cancer-associated venous thromboembolism without increasing major bleeding compared to subcutaneous dalteparin?
Oral apixaban provides a noninferior, oral alternative to subcutaneous dalteparin for the treatment of cancer-associated VTE without increasing major bleeding risk.
Answers are grounded in this paper and cite their sources.
Supports oral apixaban for cancer-associated VTE; challenges prior low-certainty evidence against its benefit.
Oral apixaban was noninferior to subcutaneous dalteparin for the treatment of cancer-associated venous thromboembolism without an increased risk of major bleeding. (Funded by the Bristol-Myers Squibb-Pfizer Alliance; Caravaggio ClinicalTrials.gov number, NCT03045406.).
No takes yet. Share an insight, caveat, or question.
Agnelli et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: